Intranasal Olopatadine-Mometasone in the Treatment of Seasonal Allergic Rhinitis

Abstract

Objective:

To review the pharmacology, efficacy, and safety of intranasal olopatadine hydrochloride-mometasone furoate (OM) combination in the treatment of seasonal allergic rhinitis (SAR).

Data sources:

The PubMed database and ClinicalTrials.gov were searched using the following terms: mometasone + olopatadine, GSP301, mometasone furoate, and olopatadine hydrochloride.

Study Selection and Data Extraction:

Articles published in English between January 1987 and August 2022 related to pharmacology, safety, and clinical trials were assessed.

Data Synthesis:

In 2 phase II clinical trials, twice-daily (BID) and once-daily (QDay) intranasal OM demonstrated significant improvements in reflective total nasal symptom score (rTNSS) (BID P < 0.001 and QDay P < 0.001) and instantaneous total nasal symptom score (iTNSS) (BID P < 0.001 and P < 0.0001; QDay P < 0.001 and P < 0.0001). In 2 phase III clinical trials, BID OM showed significant improvements in rTNSS vs. placebo (P < 0.001), olopatadine monotherapy (P = 0.03 and P = 0.003), and mometasone monotherapy (P = 0.02 and P = 0.059).

Relevance to Patient Care and Clinical Practice:

OM is indicated for treatment of SAR symptoms. Caution with use must be considered for certain high-risk patients, existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. Due to its quick and sustained onset of action, OM may be an ideal agent for initial treatment of moderate-severe SAR for patients 12 years and older.

Conclusion:

OM significantly improves SAR symptoms and is a viable treatment option in short-term SAR.

Keywords

SAR Ryaltris GSP301 olopatadine mometasone

Get full access to this article

View all access options for this article.

References

Blaiss

. Allergic rhinitis: direct and indirect costs. Allergy Asthma Proc. 2010;31:375-380.

Mudarri

. Valuing the economic costs of allergic rhinitis, acute bronchitis, and asthma from exposure to indoor dampness and mold in the US. J Environ Public Health. 2016;2016:2386596.

Tran

Vickery

Blaiss

. Management of rhinitis: allergic and non-allergic. Allergy Asthma Immunol Res. 2011;3:148-156.

Marple

Fornadley

Patel

, et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg. 2007;136(6 Suppl.):S107-S124.

Meltzer

. Allergic rhinitis: burden of illness, quality of life, comorbidities, and control. Immunol Allergy Clin North Am. 2016;36(2):235-248.

Ryalatris^® (Olopatadine hydrochloride|mometasone furoatemonohydrate) [Package Insert] Columbus, OH: Glenmark Pharmaceuticals Inc, January 2022. Accessed August 8, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211746s000lbl.pdf.

Patanase^® (Olopatadine) Nasal Spray [Package Insert]. Fort Worth, TX: Alcon Laboratories, 2009. Accessed August 8, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021861s002lbl.pdf.

Patel

Salapatek

Tantry

. Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. Ann Allergy Asthma Immunol. 2019;122:160.e1-166.e1.

Feng

Fan

Liang

Cao

. Concomitant corticosteroid nasal spray plus antihistamine (oral or local spray) for the symptomatic management of allergic rhinitis. Eur Arch Otorhinolaryngol. 2016;273:3477-3486.

10.

Prenner

. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. J Asthma Allergy. 2016;9:135-143.

11.

Harrow

Sedaghat

Caldwell-Tarr

Dufour

. A comparison of health care resource utilization and costs for patients with allergic rhinitis on single-product or free-combination therapy of intranasal steroids and intranasal antihistamines. J Manag Care Spec Pharm. 2016;22(12):1426-1436.

12.

Bangalore

Kamalakkannan

Parkar

Messerli

. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.

13.

van Galen

Nellen

Nieuwkerk

. The effect on treatment adherence of administering drugs as fixed-dose combinations versus as separate pills: systematic review and meta-analysis. AIDS Res Treat. 2014;2014:967073.

14.

Fairchild

Meltzer

Roland

Wells

Drake

Wall

. Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2007;28(6):716-723.

15.

Hochhaus

. Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy. Clin Ther. 2008;30(1):1-13.

16.

Meltzer

Hampel

Ratner

, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2005;95:600-606.

17.

Penagos

Compalati

Tarantini

Baena-Cagnani

Passalacqua

Canonica

. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Allergy. 2008;63(10):1280-1291.

18.

Simons

. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128(6):1139-1150.

19.

Berlucchi

Pedruzzi

. Intranasal mometasone furoate for treatment of allergic rhinitis. clinical medicine insights. Therapeutics. 2010;2:761-769.

20.

Lipiec

Jurkiewicz

. A new therapeutic option in the management of allergic rhinitis. Otolaryngol Pol. 2021;75:1-5.

21.

Patel

Salapatek

Talluri

Tantry

. Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations. Allergy Asthma Proc. 2018;39:232-239.

22.

Patel

Salapatek

Talluri

Tantry

. Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations. Allergy Asthma Proc. 2018;39:224-231.

23.

Nasonex (Mometasone) [Package Insert] Kenilworth ®NJ: Schering Corporation, May 2010. Accessed August 8, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020762s038lbl.pdf.

24.

Andrews

Mohar

Salhi

Tantry

. Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2020;124:171.e2-178.e2.

25.

Gross

Berman

Amar

Caracta

Tantry

. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2019;122(6):630-638.

26.

Hampel

Pedinoff

Jacobs

Caracta

Tantry

. Olopatadine-mometasone combination nasal spray: evaluation of efficacy and safety in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2019;40:261-272.

27.

Pfaar

Calderon

Andrews

, et al. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future—an EAACI Position Paper. Allergy. 2017;72(7):1035-1042.

28.

McDonnell

Weller

Pien

. Safety of intranasal steroids: an updated perspective. Curr Allergy Asthma Rep. 2020;20:69.

29.

Dykewicz

Wallace

Amrol

, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-767.

30.

Seidman

Gurgel

Lin

, et al. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152:S1-43.

31.

Nickels

Dimov

Wolf

. Pharmacokinetic evaluation of olopatadine for the treatment of allergic rhinitis and conjunctivitis. Expert Opin Drug Metab Toxicol. 2011;7(12):1593-1599.

32.

Bielory

Chun

Bielory

Canonica

. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis. Allergy. 2011;66(5):686-693.

33.

Herman

. Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost. Am J Rhinol. 2007;21(1):70-79.

34.

Chen

Zheng

Zhang

Sima

. Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2022;279:1691-1699.